Articles

Find an Article

Filter articles

Showing 11 to 20 of 712 results

Texas Uni’s sovereign immunity fail went as expected

US04-03-2021Gary Frischling

The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.

Second medical use: a regulatory perspective

UK08-02-2021Jackie Mulryne

Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.

The importance of Minerva Surgical v Hologic

US02-02-2021Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks

A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.

What 2020 means for the life sciences

International, UK15-12-2020Sally Shorthose and Rumana Khanom

Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Pricing, patents and the PMPRB in Canada

Canada14-12-2020Micheline Gravelle and Iris Cheung

Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

The doctrine of equivalents in the medtech arena

US18-11-2020Christopher Bright and Nathan Smith

The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

The plausibility battleground at the EPO

EU09-11-2020Markus Grammel

Plausibility in the context of the inventive step and sufficiency requirements can be a contentious issue before the European Patent Office. Markus Grammel of Grünecker reports.

A stricter interpretation: the EPO and antibodies

EU27-10-2020Joachim Wachenfeld and Florian Grasser

Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.

COVID-19: Protection of IP for AI tools

International, Singapore01-09-2020Mao Xiao Hong and Danny Yap

As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain.

Why Santen ends Neurim-style SPCs

EU25-08-2020Robert Stephen and Gareth Morgan

In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.

Showing 11 to 20 of 712 results

LSIPR